KRAS and cancer: This apparent 100-fold difference in the concentration required to inhibit KRAS and elicit an efficacious anti-cancer response motivated us to explore the possibility that activation of NRF2 may form an important auxiliary component of the clinical effect of G12Ci drugs in patients.